Description
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market.
Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can often produce the required number of participants in half the time, with better compliance and less costly medical professionals. Brazil and Mexico are increasingly important region, and Israel has emerged as a player in this market.
Kalorama’s Offshoring Clinical Trials: (Clinical Trial Markets in India, China, Mexico, Brazil and Israel) takes a thorough look at this market in these five important countries:
- India
- Russia
- China
- Brazil
- Mexico
- Israel
For each country profiled, the report includes the following information:
- Total Clinical Trials Revenues
for Country
- Number of Clinical Trials for Each Country
- Clinical Trials Markets by Major City
- Breakdown of Trials by Disease Category for each Country and Major Cities
- Market Drivers and Inhibitors for each country.
- Population and Disease statistics.
- Profiles of Key Companies operating in that Country
An overview of the trends driving the offshoring of clinical trials and future possiblities in BRIC and Israel is also included. The report addresses the following trends:
- Evolving Regulatory Environments
- Government Support of Clinical Research
- Good Clinical Practice Guidelines
- Import/Export Restrictions
- Economic Conditions
- Structure of Public Health Systems
- Country Literacy Rates
- Intellectual Property Protection
- Large Populations
This report combines extensive secondary research into the clinical trials markets with interviews with market leaders. For the purpose of this study Kalorama Information conducted interviews with more than 30 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue in this report.
Profiles for active companies in each region are included. Several hundred companies compete worldwide for clinical trial research contracts. These companies consist of large pharmaceutical companies, niche drug developers and marketers and contract research organizations (CROs).
Company profiles included in the study are:
- AAIPharma, Inc.
- Accell Clinical Research, LLC
- Accutest Research Laboratories Pvt. Ltd.
- Cato Research Israel
- ClinInvent Research Pvt. Ltd.
- Congenix
- Criterium, Inc.
- GleneaglesCRC Pte Ltd
- Hesperion Russia
- Kendle
- InnoPharm Ltd.
- LAXAI India Pvt. Ltd.
- Manipal Acunova Ltd.
- Mmatiss
- PharmaSeed Ltd.
- PHDS Healthcare Research
- ProMedica Clinical Research LLC
- Quintiles Asia, Inc.
- SIRO Clinpharm Pvt. Ltd.
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Company Profiles
Chapter Two: Introduction
- Clinical Trials Overview
- Regulatory Environment
- Overview
- Demographics and Statistics
- Worldwide Demographics
- Incidence, Prevalence of Disease
Chapter Three: Clinical Trials in India
- Overview
- Country Demographics
- Clinical Trials Analysis in India
- Mumbai
- Delhi
- Kolkatta (formerly Calcutta)
- Bangalore
- Issues and Trends
- Literacy Rates
- Regulatory Environment and Government Support
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- Accutest Research Laboratories Pvt. Ltd.
- ClinInvent Research Pvt. Ltd.
- SIRO Clinpharm Pvt. Ltd.
- Manipal Acunova Ltd.
Chapter FouR: Clinical Trials in Russia
- Overview
- Country Demographics
- Clinical Trials Analysis in Russia
- Moscow
- St. Petersburg
- Novosibirsk
- Nizhniy Novgorod
- Issues and Trends
- Regulatory Environment and Government Support
- Government Restrictions
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- Accell Clinical Research, LLC
- Congenix
- Hesperion Russia
- InnoPharm Ltd.
Chapter Five: Clinical Trials in China
- Overview
- Country Demographics
- Clinical Trials Analysis in China
- Shanghai
- Beijing
- Hong Kong
- Tianjin
- Issues and Trends
- Regulatory Environment and Government Support
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- GleneaglesCRC Pte Ltd
- PHDS Healthcare Research
- Quintiles Asia, Inc.
Chapter Six: Clinical Trials in Brazil
- Overview
- Country Demographics
- Clinical Trials Analysis in Brazil
- Sao Paulo
- Belo Horizonte
- Rio de Janeiro
- Salvador
- Issues and Trends
- Regulatory Environment and Government Support
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- ProMedica Clinical Research LLC
- AAIPharma, Inc.
Chapter Seven: Clinical Trials in Mexico
- Overview
- Country Demographics
- Clinical Trials Analysis in Mexico
- Mexico City
- Guadalajara
- Puebla
- Tijuana
- Issues and Trends
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- Mmatiss
- Kendle
Chapter Eight: Clinical Trials in Israel
- Overview
- Country Demographics
- Clinical Trials Analysis in Israel
- Jerusalem
- Tel Aviv
- Haifa
- Rishon Lezion
- Issues and Trends
- Regulatory Environment and Government Support
- Market Analysis
- Market Drivers and Inhibitors
- Market Size and Growth
- Company Profiles
- Cato Research Israel
- Criterium, Inc.
- PharmaSeed Ltd.
Chapter One: Executive Summary
- Table 1-1: Clinical Trial Market in Select Country 2006-2012
- Figure 1-1: Clinical Trial Market in Select Country 2006 and 2012
- Figure 1-2: Clinical Trial Market – Six Developing Markets vs. United States
- and Rest of World Markets, 2006
- Table 1-2: Clinical Trials in Six Developing Markets by Disease/Condition
- Figure 1-3: Clinical Trials in Six Developing Markets by Disease/Condition
chapter Two: Introduction
- Table 2-1: Clinical Trial Overview
- Table 2-2: Registered Clinical Trials by Select Country
- Figure 2-1: Registered Clinical Trials by Select Country
- Table 2-3: Regulatory Agencies by Country
- Table 2-4: World Population by Selected Geographical Region, 2006-2050
- Figure 2-2: World Population by Selected Geographical Region, 2006-2050
- Table 2-5: Estimated World Population by Age and Geographical Region, 2006
- Figure 2-3: Estimated World Population by Age and Geographical Region, 2006
- Table 2-6: Worldwide and United States Incidence/Prevalence of Disease or Condition, Estimated 2006
Chapter Three: Clinical Trials in India
- Table 3-1: India – Midyear Population, by Age and Sex
- Figure 3-1: India – Midyear Population, by Age
- Table 3-2: Registered Clinical Trials in India by Metro Area
- Figure 3-2: Registered Clinical Trials in India by Metro Area
- Table 3-3: Registered Clinical Trials in India by Disease, Condition, and/or Specialty
- Figure 3-3: Registered Clinical Trials in India by Disease, Condition, and/or Specialty
- Table 3-4: Clinical Trials in Mumbai, India by Disease/Condition
- Figure 3-5: Clinical Trials in Mumbai, India – Distribution by Disease/Condition
- Figure 3-6: Clinical Trials in Mumbai, India by Disease/Condition
- Table 3-5: Clinical Trials in Delhi, India by Disease/Condition
- Figure 3-7: Clinical Trials in Delhi, India – Distribution by Disease/Condition
- Figure 3-8: Clinical Trials in Delhi, India by Disease/Condition
- Table 3-6: Clinical Trials in Kolkata (Calcutta), India by Disease/Condition
- Figure 3-9: Clinical Trials in Kolkata (Calcutta), India by Disease/Condition
- Table 3-7: Clinical Trials in Bangalore, India by Disease/Condition
- Figure 3-10: Clinical Trials in Bangalore, India – Distribution by Disease/Condition
- Figure 3-11: Clinical Trials in Bangalore, India by Disease/Condition
- Table 3-8: Number of Literates and Literacy Rate, India
- Table 3-9: Comparison of Clinical Trail Market Drivers and Inhibitors – India
- Table 3-10: Clinical Trial Market in India 2006-2012
- Figure 3-12: Clinical Trial Market in India 2006-2012
- Figure 3-13: Clinical Trial Market – India vs. World Markets, 2006
Chapter FouR: Clinical Trials in Russia
- Table 4-1: Russia – Midyear Population, by Age and Sex
- Figure 4-1: Russia – Midyear Population, by Age
- Table 4-2: Registered Clinical Trials in Russia by Metro Area
- Figure 4-2: Registered Clinical Trials in Russia by Metro Area
- Table 4-3: Registered Clinical Trials in Russia by Disease, Condition, and/or Specialty
- Figure 4-3: Registered Clinical Trials in Russia by Disease, Condition, and/or Specialty
- Table 4-4: Clinical Trials in Moscow, Russia by Disease/Condition
- Figure 4-4: Clinical Trials in Moscow, Russia – Distribution by Disease/Condition
- Figure 4-5: Clinical Trials in Moscow, Russia by Disease/Condition
- Table 4-5: Clinical Trials in St. Petersburg, Russia by Disease/Condition
- Figure 4-6: Clinical Trials in St. Petersburg, Russia – Distribution by Disease/Condition
- Figure 4-7: Clinical Trials in St. Petersburg, Russia by Disease/Condition
- Table 4-6: Clinical Trials in Novosibirsk, Russia by Disease/Condition
- Figure 4-8: Clinical Trials in Novosibirsk, Russia – Distribution by Disease/Condition
- Figure 4-9: Clinical Trials in Novosibirsk, Russia by Disease/Condition
- Table 4-7: Clinical Trials in Nizhniy Novgorod, Russia by Disease/Condition
- Figure 4-10: Clinical Trials in Nizhniy Novgorod, Russia – Distribution by Disease/Condition
- Figure 4-11: Clinical Trials in Nizhniy Novgorod, Russia by Disease/Condition
- Table 4-8: Comparison of Clinical Trail Market Drivers and Inhibitors – Russia
- Table 4-9: Clinical Trial Market in Russia 2006-2012 Compound Annual Growth Rate
- Figure 4-12: Clinical Trial Market in Russia 2006-2012
- Figure 4-13: Clinical Trial Market – Russia vs. World Markets, 2006
Chapter Five: Clinical Trials in China
- Table 5-1: China – Midyear Population, by Age and Sex
- Figure 5-1: China – Midyear Population, by Age, 2006 and 2012
- Table 5-2: Registered Clinical Trials in China by Metro Area
- Figure 5-2: Registered Clinical Trials in China by Metro Area
- Table 5-3: Registered Clinical Trials in China by Disease, Condition, and/or Specialty
- Figure 5-3: Registered Clinical Trials in China by Disease, Condition, and/or Specialty
- Table 5-4: Clinical Trials in Shanghai, China by Disease/Condition
- Figure 5-4: Clinical Trials in Shanghai, China Distributionby Disease/Condition
- Figure 5-5: Clinical Trials in Shanghai, China by Disease/Condition
- Table 5-5: Clinical Trials in Beijing, China by Disease/Condition
- Figure 5-6: Clinical Trials in Beijing, China – Distribution by Disease/Condition
- Figure 5-7: Clinical Trials in Beijing, China by Disease/Condition
- Table 5-6: Clinical Trials in Hong Kong, China by Disease/Condition Clinical Trials in Hong Kong, China – Distribution by Disease/Condition
- Figure 5-9: Clinical Trials in Hong Kong, China by Disease/Condition
- Table 5-7: Clinical Trials in Tianjin, China by Disease/Condition
- Figure 5-10: Clinical Trials in Tianjin, China – Distribution by Disease/Condition
- Figure 5-11: Clinical Trials in Tianjin, China by Disease/Condition
- Table 5-8: Comparison of Clinical Trail Market Drivers and Inhibitors – China
- Table 5-9: Clinical Trial Market in China 2006-2012
- Figure 5-12: Clinical Trial Market in China 2006-2012
- Figure 5-13: Clinical Trial Market – China vs. World Markets, 2006
Chapter Six: Clinical Trials in Brazil
- Table 6-1: Brazil – Midyear Population, by Age and Sex
- Figure 6-1: Brazil – Midyear Population, by Age and Sex, 2006 and 2012
- Table 6-2: Registered Clinical Trials in Brazil by Metro Area
- Figure 6-2: Registered Clinical Trials in Brazil by Metro Area
- Table 6-3: Registered Clinical Trials in Brazil by Disease, Condition, and/or Specialty
- Figure 6-3: Registered Clinical Trials in Brazil by Disease, Condition, and/or Specialty
- Table 6-4: Clinical Trials in Sao Paulo, Brazil by Disease/Condition
- Figure 6-4: Clinical Trials in Sao Paulo, Brazil – Distribution by Disease/Condition
- Figure 6-5: Clinical Trials in Sao Paulo, Brazil by Disease/Condition
- Table 6-5: Clinical Trials in Belo Horizonte, Brazil by Disease/Condition
- Figure 6-6: Clinical Trials in Belo Horizonte, Brazil – Distribution by Disease/Condition
- Figure 6-7: Clinical Trials in Belo Horizonte, Brazil by Disease/Condition
- Table 6-6: Clinical Trials in Rio de Janeiro, Brazil by Disease/Condition
- Figure 6-8: Clinical Trials in Rio de Janeiro, Brazil – Distribution by Disease/Condition
- Figure 6-9: Clinical Trials in Rio de Janeiro, Brazil by Disease/Condition
- Table 6-7: Clinical Trials in Salvador, Brazil by Disease/Condition
- Figure 6-10: Clinical Trials in Salvador, Brazil – Distribution by Disease/Condition
- Figure 6-11: Clinical Trials in Salvador, Brazil by Disease/Condition
- Table 6-8: Comparison of Clinical Trail Market Drivers and Inhibitors – Brazil
- Table 6-9: Clinical Trial Market in Brazil 2006-2012
- Figure 6-12: Clinical Trial Market in Brazil 2006-2012
- Figure 6-13: Clinical Trial Market – Brazil vs. World Markets, 2006
Chapter Seven: Clinical Trials in Mexico
- Table 7-1: Mexico – Midyear Population, by Age and Sex
- Figure 7-1: Mexico – Midyear Population, by Age and Sex
- Table 7-2: Registered Clinical Trials in Mexico by Metro Area
- Figure 7-2: Registered Clinical Trials in Mexico by Metro Area
- Table 7-3: Registered Clinical Trials in Mexico by Disease, Condition, and/or Specialty
- Figure 7-3: Registered Clinical Trials in Mexico by Disease, Condition, and/or Specialty
- Table 7-4: Clinical Trials in Mexico City, Mexico by Disease/Condition
- Figure 7-4: Clinical Trials in Mexico City, Mexico – Distribution by Disease/Condition
- Figure 7-5: Clinical Trials in Mexico City, Mexico by Disease/Condition
- Table 7-5: Clinical Trials in Guadalajara, Mexico by Disease/Condition
- Figure 7-6: Clinical Trials in Guadalajara, Mexico – Distribution by Disease/Condition
- Figure 7-7: Clinical Trials in Guadalajara, Mexico by Disease/Condition
- Table 7-6: Clinical Trials in Puebla, Mexico by Disease/Condition
- Figure 7-8: Clinical Trials in Puebla, Mexico – Distribution by Disease/Condition
- Figure 7-9: Clinical Trials in Puebla, Mexico by Disease/Condition
- Table 7-7: Clinical Trials in Tijuana, Mexico by Disease/Condition
- Figure 7-10: Clinical Trials in Tijuana, Mexico – Distribution by Disease/Condition.
- Figure 7-11: Clinical Trials in Tijuana, Mexico by Disease/Condition
- Table 7-8: Comparison of Clinical Trail Market Drivers and Inhibitors – Mexico
- Table 7-9: Clinical Trial Market in Mexico 2006-2012
- Figure 7-12: Clinical Trial Market in Mexico 2006-2012
- Figure 7-13: Clinical Trial Market – Mexico vs. World Markets, 2006
Chapter Eight: Clinical Trials in Israel
- Table 8-1: Israel – Midyear Population, by Age and Sex
- Figure 8-1: Israel – Midyear Population, by Age and Sex, 2006 and 2012
- Table 8-2: Registered Clinical Trials in Israel by Metro Area
- Figure 8-2: Registered Clinical Trials in Israel by Metro Area
- Table 8-3: Registered Clinical Trials in Israel by Disease, Condition, and/or Specialty
- Figure 8-3: Registered Clinical Trials in Israel by Disease, Condition, and/or Specialty
- Table 8-4: Clinical Trials in Jerusalem, Israel by Disease/Condition
- Figure 8-4: Clinical Trials in Jerusalem, Israel – Distribution by Disease/Condition..
- Figure 8-5: Clinical Trials in Jerusalem, Israel by Disease/Condition
- Table 8-5: Clinical Trials in Tel Aviv, Israel by Disease/Condition
- Clinical Trials in Tel Aviv, Israel – Distribution by Disease/Condition
- Figure 8-7: Clinical Trials in Tel Aviv, Israel by Disease/Condition
- Table 8-6: Clinical Trials in Haifa, Israel by Disease/Condition
- Figure 8-8: Clinical Trials in Haifa, Israel – Distribution by Disease/Condition
- Figure 8-9: Clinical Trials in Haifa, Israel by Disease/Condition
- Table 8-7: Clinical Trials in Rishon Lezion, Israel by Disease/Condition
- Figure 8-10: Clinical Trials in Rishon Lezion – Distribution by Disease/Condition
- Figure 8-11: Clinical Trials in Rishon Lezion, Israel by Disease/Condition
- Table 8-8: Comparison of Clinical Trail Market Drivers and Inhibitors -Israel
- Table 8-9: Clinical Trial Market in Israel 2006-2012
- Figure 8-12: Clinical Trial Market in Israel 2006-2012
- Figure 8-13: Clinical Trial Market – Israel vs. World Markets, 2006
